Keros Therapeutics, Inc. (KROS) trades at a trailing P/E of 5.3. Trailing earnings yield is 18.86%. Graham Number is $20.70.
Criteria proven by this page:
Overall SharesGrow Score: 78/100 with 5/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -133.6 | 0.00 | 13.98 | 17.84 | - |
| 2019 | -14.4 | -0.02 | 360.31 | 17.84 | - |
| 2020 | -24.1 | -0.22 | 4.18 | 0.00 | - |
| 2021 | -23.2 | 1.66 | 5.61 | 67.92 | - |
| 2022 | -11.6 | -0.18 | 4.37 | 0.00 | - |
| 2023 | -7.7 | -0.30 | 3.52 | 7,753.76 | - |
| 2024 | -3.2 | 0.82 | 1.04 | 166.94 | - |
| 2025 | 8.7 | -0.06 | 2.50 | 3.11 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-0.15 | $10M | $-1.34M | -13.4% |
| 2019 | $-1.39 | $10M | $-12.34M | -123.4% |
| 2020 | $-2.93 | $0.00 | $-45.36M | - |
| 2021 | $-2.52 | $20.1M | $-58.74M | -292.3% |
| 2022 | $-4.15 | $0.00 | $-104.68M | - |
| 2023 | $-5.20 | $151K | $-152.99M | -101319.2% |
| 2024 | $-5.00 | $3.55M | $-187.35M | -5277.5% |
| 2025 | $2.30 | $244.06M | $87.01M | 35.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-4.89 | $-8.84 – $-1.25 | $10.29M | $2.8M – $14.04M | 7 |
| 2027 | $-5.75 | $-11.62 – $-3.39 | $13.08M | $908K – $29.48M | 7 |
| 2028 | $-4.97 | $-19.02 – $-0.86 | $53.6M | $53.6M – $53.6M | 8 |
| 2029 | $-5.70 | $-13.36 – $0.82 | $69.5M | $8.33M – $141.28M | 6 |
| 2030 | $-7.08 | $-16.59 – $1.02 | $85.21M | $10.22M – $173.21M | 6 |
